# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Pliant Therapeutics, Inc. (NASDAQ:PLRX), a late-stage biotechnology company and leader in the discovery and development of nove...
HC Wainwright & Co. analyst Ed Arce maintains Pliant Therapeutics (NASDAQ:PLRX) with a Buy and raises the price target f...
Cantor Fitzgerald analyst Pete Stavropoulos reiterates Pliant Therapeutics (NASDAQ:PLRX) with a Overweight.
Oppenheimer analyst Jeff Jones maintains Pliant Therapeutics (NASDAQ:PLRX) with a Outperform and lowers the price target fro...
Needham analyst Joseph Stringer reiterates Pliant Therapeutics (NASDAQ:PLRX) with a Buy and maintains $38 price target.
Pliant Therapeutics (NASDAQ:PLRX) reported quarterly losses of $(0.92) per share which missed the analyst consensus estimate of...
Needham analyst Joseph Stringer reiterates Pliant Therapeutics (NASDAQ:PLRX) with a Buy and maintains $38 price target.
HC Wainwright & Co. analyst Ed Arce reiterates Pliant Therapeutics (NASDAQ:PLRX) with a Buy and maintains $36 price target.
Bexotegrast at 320 mg was well tolerated up to 40 weeks of treatment with no treatment-related severe or serious adverse events...